Wise Practice of Chinese Hemodialysis (WISHES)

NCT03001921 · tracked via the Priya Life Science China tracker

Sponsor

Sun Yat-sen University

Phase

Observational

Started

2013-12

Last updated

2026-09-15

Condition(s) studied

Haemolyses and Related Conditions

Investigational drug(s) / intervention(s)

No intervention

No intervention: Registration of all HD patients in the First Affiliated Hospital of Sun Yat-sen University and other hospital which have signed the contract in China.

Study summary

The investigators are registering all HD patients at recruited hospitals and developing a HD database in China. Patients will be follow-up every 3 months, and both baseline and follow-up information will be entered into the registration system. The patient survival, technical survival, patency rate of access, quality of life and residual renal function for HD patients will be compared using the HD database.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: End stage renal disease patients receiving hemodialysis treatment. Exclusion Criteria: No

Primary outcome measure(s)

Patient survival of HD patients — 10 years

Trial sites (1)

Facility	City	Region	Status
The 1st Affiliated Hospital, Sun Yet-sen University	Guangzhou	Guangdong	Recruiting

More Sun Yat-sen University trials in China

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC Active, not recruiting

Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer Recruiting

Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma Recruiting

Phacotrabeculectomy Versus Phacogoniotomy (PVP) in Advanced Primary Angle-closure Glaucoma Active, not recruiting

Myeloprotection With Trilaciclib in Pan-cancer Population Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03001921 on ClinicalTrials.gov ↗ ← All trials in China